Pfizer Reports Positive Late-Stage Trial Results for Vitiligo Drug Litfulo
Pfizer (PFE) announced that its oral Janus kinase inhibitor, Litfulo, met the primary endpoints in two late-stage clinical trials for nonsegmental vitiligo. The drug is being tested as a treatment for an autoimmune condition marked by white patches on skin and hair. The topline data from these trials represents a significant milestone for Pfizer's dermatology portfolio. If approved, Litfulo could become the first oral therapy available for this patient population, potentially expanding market opportunities in the autoimmune disease space.
Tickers: $PFE